Catalyst Calendar
Scope

Sat, May 30, 2026

1 updates
BNTX
2:15 PM

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig

Interim Data • Phase 2ASCO oral presentation Sat, May 30, 2026biontech.de

Fri, May 22, 2026

1 updates
BNTX
5:00 AM

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with

Presentation / Abstract • Phase 2/3ASCO oral presentation Sat, May 30, 2026, 1:15 PM CDTbiontech.de

Fri, May 15, 2026

1 updates

Thu, May 7, 2026

1 updates
BNTX
6:45 AM

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary

biontech.de

Tue, May 5, 2026

1 updates

Tue, Apr 21, 2026

1 updates